Following the interview of Dr. Nathalie Cugnardey, Medical Director Europe Mylan laboratories.
Why is the Mylan Lab involved so much in the fight against AIDS?
Dr Nathalie Cugnardey: Mylan has been particularly involved for 10 years in the fight against HIV / AIDS. Since 2003, Mylan has been providing quality active ingredients to generic antiretroviral manufacturers.
In 2007, the company began offering finished products and launched a range of pediatric and adult ARVs. Today, Mylan is widely respected for the quality, reliability and accessibility of its ARV franchise, which allows the laboratory to be a leading player in this sector or in the care of HIV / AIDS.
What types of actions have you taken to help developing countries?
Dr. NC: Mylan has proposed a number of ARV innovations in developing countries, such as the production of packaged "combo packs" and new heat-resistant ARVs. In addition, Mylan is one of the world leaders in the production of pediatric formulations.
In 2012, thanks to these innovations, we provided 43 ARV drugs in more than 120 countries. Today, these products help around 40% of people receiving HIV / AIDS treatment in developing countries.
Mylan's progress in the fight against HIV / AIDS also reflects its strong partnerships with many organizations that share its humanitarian goals. Many of these organizations, such as the Bill and Melinda Gates Foundation and the Clinton Initiative (or CHAI), focus in part on obtaining a reliable and accessible ARV supply, and have found in our laboratory a partner of choice .
Does the lab sponsor events that raise awareness and raise funds for important causes?
Dr. NC: Yes. So the World Team Tennis's Smash Hits competition, supports several charities, like the Elton John Foundation Against AIDS. In addition, the lab is a member of the Global Business Coalition on HIV / AIDS, Tuberculosis and Malaria (GBC), the leading business organization leading the fight against illness and discrimination in the workplace that can to accompany.
Mylan has also entered into licensing agreements with Bristol-Myers Squibb, Gilead Sciences, Merck and ViiV, enabling it to produce and market generic versions of many of its ARVs in developing countries.
Mylan's commitment in this fight demonstrates that its goal is to go beyond the mere production of generic drugs, but also to address unmet medical needs and ensure accessibility to drugs.
To read: A generic medicine is not quite identical to the original medicine (princeps) ...